Presentation is loading. Please wait.

Presentation is loading. Please wait.

Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small.

Published byLizbeth Francis Modified over 5 years ago

Similar presentations

Presentation on theme: "Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small."— Presentation transcript:

1 Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF ) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Lyudmila Bazhenova, MD, D. Ross Camidge, MD, PhD, Benjamin J. Solomon, MBBS, PhD, June Herman, MD, Tatiana Kain, MD, Yung-Jue Bang, MD, PhD, Eunice L. Kwak, MD, PhD, Alice T. Shaw, MD, PhD, Ravi Salgia, MD, PhD, Robert G. Maki, MD, PhD, Jeffrey W. Clark, MD, Keith D. Wilner, PhD, A. John Iafrate, MD, PhD  Journal of Thoracic Oncology  Volume 5, Issue 12, Pages (December 2010) DOI: /JTO.0b013e318200f9ff Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 Break-apart ALK FISH assay. FISH, fluorescent in situ hybridization. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e318200f9ff) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A, Coronal diagnostic CT/PET fusion images 7 days before starting crizotinib. B, Coronal diagnostic CT/18-FDG PET fusion images 14 days after starting crizotinib. CT, computed tomography; 18-FDG PET, 18F-fluorodeoxyglucose positron emission tomography. Journal of Thoracic Oncology 2010 5, DOI: ( /JTO.0b013e318200f9ff) Copyright © 2010 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small."

Similar presentations

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.

Choroidal Metastases Responsive to Crizotinib Therapy in a Lung Adenocarcinoma Patient with ALK 2p23 Fusion Identified by ALK Immunohistochemistry Yan.
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.

Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.
Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies  Sai-Hong Ignatius Ou, MD,
Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in.

Tolerable and Effective Combination of Full-Dose Crizotinib and Osimertinib Targeting MET Amplification Sequentially Emerging after T790M Positivity in.
Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer  Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,
Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer  Sai-Hong Ignatius Ou, MD, PhD, Jason.
ALK FISH and IHC: You Cannot Have One without the Other

ALK FISH and IHC: You Cannot Have One without the Other
Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.

Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy  Deepa Rangachari, MD, Xiuning.
Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.
Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer  Ernest Nadal,

Paraneoplastic Opsoclonus-Myoclonus Syndrome as a New and Single Manifestation of Relapsing Disease in a Patient with Small Cell Lung Cancer  Ernest Nadal,
Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation  Andrea L.H. Arnett, MD, PhD, Kenneth.

Utility of 18F-FDG PET for Predicting Histopathologic Response in Esophageal Carcinoma following Chemoradiation  Andrea L.H. Arnett, MD, PhD, Kenneth.
Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration 

Treatment of Lung Cancer with an ALK Inhibitor After EML4-ALK Fusion Gene Detection Using Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration 
Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH5424802/RO5424802)

Next-Generation Sequencing Reveals a Novel NSCLC ALK F1174V Mutation and Confirms ALK G1202R Mutation Confers High-Level Resistance to Alectinib (CH /RO )
Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.

Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer  Eiko Theodora Browning, MD, Andrew James.
A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib  Trish Thorne-Nuzzo, BS, Crystal.
Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.

Patient-Reported Outcomes and Quality of Life in PROFILE 1007: A Randomized Trial of Crizotinib Compared with Chemotherapy in Previously Treated Patients.
MET-Mutated NSCLC with Major Response to Crizotinib

MET-Mutated NSCLC with Major Response to Crizotinib
Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,

Responses to Crizotinib Can Occur in High-Level MET-Amplified Non–Small Cell Lung Cancer Independent of MET Exon 14 Alterations  Rafael Caparica, MD,
Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

Resection of Mucinous Lung Adenocarcinoma Presenting with Intractable Bronchorrhea  Motoshi Takao, MD, PhD, Takehiro Takagi, MD, Hitoshi Suzuki, MD, PhD,

Similar presentations

Ads by Google